Table 2.

New CINV agents†

Drug	Half‐life (h)	Preparation	Common side‐effects	Principal use
5HT3‐RA
Ondansetron	4–11	Oral	Headache, constipation	Acute CINV (HEC and MEC)
Granisetron	9	IV
Palonosetron	40	Oral or IV		Acute and delayed CINV (HEC and MEC)
NK1‐RA
Aprepitant	9	Oral	Diarrhoea constipation, fatigue, hiccups, elevated hepatic aminotransferases	Acute CINV (HEC, carboplatin (AUC > 4) and oxaliplatin regimens and as rescue for other MEC with prior episode of CINV)
Fosaprepitant (aprepitant prodrug)	14	IV
5HT3‐RA + NK1‐RA
Palonosetron + netupitent	88	Oral	Headache, constipation	Acute CINV (HEC)
Atypical anti‐psychotic
Olanzapine	30	Oral	Sedation	Adjunct use in acute CINV (HEC)

^†Adapted from product information and eviQ guidelines. ³ , ⁴

5HT3‐RA, 5‐hydroxytryptamine type 3‐receptor antagonists; CINV, chemotherapy‐induced nausea and vomiting; HEC, highly emetogenic chemotherapy; IV, intravenous; MEC, moderate emetogenic chemotherapy; NK1‐RA, neurokinin‐1‐receptor antagonists.